Sugi Predict

Sugi Predict / Compounds / SCHEMBL567975

SCHEMBL567975

SCHEMBL567975

COC(=O)c1cc(Cl)nc(OC)c1

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 5/20 0.76
▸ KDM4E B2RXH2 3/20 0.76
▸ TAS1R3 Q7RTX0 1/20 0.53
▸ TAS1R1 Q7RTX1 1/20 0.53
▸ TAS1R2 Q8TE23 1/20 0.53
▸ SMN1; SMN2 Q16637 3/20 0.50
▸ L3MBTL1 Q9Y468 3/20 0.49
▸ CA1 P00915 2/20 0.46
▸ CA2 P00918 2/20 0.46
▸ CA12 O43570 1/20 0.46
▸ CA7 P43166 1/20 0.46
▸ CA9 Q16790 1/20 0.46
▸ CA14 Q9ULX7 1/20 0.46
▸ LMNA P02545 1/20 0.44
▸ POLB P06746 1/20 0.44
▸ GAA P10253 1/20 0.44
▸ NFKB1 P19838 1/20 0.44
▸ XDH P47989 1/20 0.44
▸ GFER P55789 1/20 0.44
▸ NFKB2 Q00653 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31287794 1.00 ALDH1A1 (0.76) ALDH1A1KDM4ETAS1R3TAS1R1TAS1R2
SCHEMBL6964278 0.88 ALDH1A1 (0.58) ALDH1A1KDM4ETAS1R3TAS1R1TAS1R2
SCHEMBL569249 0.87 ALDH1A1 (0.59) ALDH1A1KDM4ESMN1; SMN2L3MBTL1CA1
Hydrochloric Acid SCHEMBL29890892 0.85 ALDH1A1 (0.57) ALDH1A1KDM4ESMN1; SMN2L3MBTL1CA1
SCHEMBL837798 0.84 ALDH1A1 (0.56) ALDH1A1KDM4ETAS1R3TAS1R1TAS1R2
SCHEMBL931870 0.84 ALDH1A1 (0.52) ALDH1A1KDM4ETAS1R3TAS1R1TAS1R2
SCHEMBL5761347 0.84 ALDH1A1 (0.52) ALDH1A1KDM4ETAS1R3TAS1R1TAS1R2
SCHEMBL28845230 0.83 ALDH1A1 (0.53) ALDH1A1KDM4ETAS1R3TAS1R1TAS1R2
SCHEMBL2711566 0.83 ALDH1A1 (0.53) ALDH1A1KDM4ETAS1R3TAS1R1TAS1R2
SCHEMBL1179421 0.83 SMN1; SMN2 (0.55) ALDH1A1KDM4ETAS1R3TAS1R1TAS1R2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 146 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260015743-A1 MEDIATED HYDROGEN ANODE FOR USE IN REDUCTIVE ELECTROSYNTHESIS WISCONSIN ALUMNI RES FOUND (US) 2026-01-15 — — US disclosed
US-20250346574-A1 PYRIDINYL SUBSTITUTED OXOISOINDOLINE COMPOUNDS FOR THE TREATMENT OF CANCER BRISTOL-MYERS SQUIBB COMPANY (US) 2025-11-13 — — US disclosed
EP-4585265-A2 HETEROARYL INHIBITORS OF PLASMA KALLIKREIN Takeda Pharmaceutical Company Limited (JP) 2025-07-16 — — EP disclosed
WO-2025090792-A1 AMIDE PRODRUGS AND USES THEREOF AUTOBAHN THERAPEUTICS, INC. (US) 2025-05-01 — — WO disclosed
US-20250136607-A1 PAD4 INHIBITORS AND USE THEREOF REGOR PHARMACEUTICALS, INC. 2025-05-01 — — US disclosed
US-20240342292-A1 Compounds for the Degradation of EGFR Kinase BEIGENE SWITZERLAND GMBH (CH) 2024-10-17 — — US disclosed
EP-4444724-A1 COMPOUNDS FOR THE DEGRADATION OF EGFR KINASE BeiGene Switzerland GmbH (CH) 2024-10-16 — — EP disclosed
EP-4433477-A1 PAD4 INHIBITORS AND USE THEREOF Regor Pharmaceuticals, Inc. (US) 2024-09-25 — — EP disclosed
CN-118679162-A PAD4 inhibitors and uses thereof 锐格药业公司 2024-09-20 — — CN disclosed
US-20240228488-A1 HETEROARYL INHIBITORS OF PLASMA KALLIKREIN TAKEDA PHARMACEUTICALS CO (JP) 2024-07-11 — — US disclosed
US-20070225372-A1 Amides as Bace Inhibitors ELI LILLY AND COMPANY 2007-09-27 — — US disclosed
US-20070213331-A1 PYRROLIDINE DERIVATIVES USEFUL AS BASE INHIBITORS ELI LILLY AND COMPANY 2007-09-13 — — US disclosed
EP-1740575-A2 PYRROLIDINE DERIVATIVES USEFUL AS BACE INHIBITORS ELI LILLY AND COMPANY (US) 2007-01-10 — — EP disclosed
EP-1740573-A1 AMIDES AS BACE INHIBITORS ELI LILLY AND COMPANY (US) 2007-01-10 — — EP disclosed
WO-2005108391-A1 AMIDES AS BACE INHIBITORS ELI LILLY AND COMPANY (US) 2005-11-17 — — WO disclosed
WO-2005108358-A2 PYRROLIDINE DERIVATIVES USEFUL AS BACE INHIBITORS ELI LILLY AND COMPANY (US) 2005-11-17 — — WO disclosed
EP-1329160-A2 4-ACYLAMINOPYRAZOLE DERIVATIVES Sankyo Company, Limited (JP) 2003-07-23 — — EP disclosed
EP-0351399-A1 ISOQUINOLINE DERIVATIVES, THEIR MANUFACTURE AND USE HUHTAMÄKI OY (FI) 1990-01-24 — — EP disclosed
WO-1988007041-A1 ISOQUINOLINE DERIVATIVES, THEIR MANUFACTURE AND USE Huhtamäki Oy (FI) 1988-09-22 — — WO disclosed
US-4474602-A Substituted pyridyl compounds, herbicidal compositions and method of use THE DOW CHEMICAL COMPANY (US) 1984-10-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260015743-A1 MEDIATED HYDROGEN ANODE FOR USE IN REDUCTIVE ELECTROSYNTHESIS HAO2, HACL2, HVCN1 ALDH1A1 246/4885KDM4E 3823/4885TAS1R3 3552/4885
US-20070225372-A1 Amides as Bace Inhibitors BACE2, BACE1, APP ALDH1A1 661/4885KDM4E 453/4885TAS1R3 4244/4885
US-20250136607-A1 PAD4 INHIBITORS AND USE THEREOF PADI4, PADI6, PADI2 ALDH1A1 273/4885KDM4E 172/4885TAS1R3 2502/4885
US-20240228488-A1 HETEROARYL INHIBITORS OF PLASMA KALLIKREIN KLKB1, KLK5, KLK1 ALDH1A1 3026/4885KDM4E 796/4885TAS1R3 4367/4885
US-20250346574-A1 PYRIDINYL SUBSTITUTED OXOISOINDOLINE COMPOUNDS FOR THE TREATMENT OF CANCER RECQL, H1-5, H1-3 ALDH1A1 3170/4885KDM4E 1694/4885TAS1R3 4576/4885
US-20070213331-A1 PYRROLIDINE DERIVATIVES USEFUL AS BASE INHIBITORS BACE1, BACE2, PSEN1 ALDH1A1 1523/4885KDM4E 1975/4885TAS1R3 4157/4885
US-20240342292-A1 Compounds for the Degradation of EGFR Kinase EGFR, ERBB2, ERBB3 ALDH1A1 3644/4885KDM4E 1776/4885TAS1R3 3683/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.